WO2016107879A3 - New use of angiotensin ii receptor agonists - Google Patents

New use of angiotensin ii receptor agonists Download PDF

Info

Publication number
WO2016107879A3
WO2016107879A3 PCT/EP2015/081369 EP2015081369W WO2016107879A3 WO 2016107879 A3 WO2016107879 A3 WO 2016107879A3 EP 2015081369 W EP2015081369 W EP 2015081369W WO 2016107879 A3 WO2016107879 A3 WO 2016107879A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
receptor
new use
receptor agonists
agonists
Prior art date
Application number
PCT/EP2015/081369
Other languages
French (fr)
Other versions
WO2016107879A2 (en
Inventor
Björn DAHLÖF
Anders Ljunggren
Po Sing LEUNG
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of WO2016107879A2 publication Critical patent/WO2016107879A2/en
Publication of WO2016107879A3 publication Critical patent/WO2016107879A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a new use of compounds that are angiotensin II (Ang II) receptor agonists, more particularly agonists of the Ang II type 2 receptor (the AT2 receptor), and especially non-peptide agonists that bind selectively to the AT2 receptor, for adjuvant administration in stem cell and progenitor cell therapy.
PCT/EP2015/081369 2014-12-30 2015-12-29 New use of angiotensin ii receptor agonists WO2016107879A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098185P 2014-12-30 2014-12-30
US62/098,185 2014-12-30

Publications (2)

Publication Number Publication Date
WO2016107879A2 WO2016107879A2 (en) 2016-07-07
WO2016107879A3 true WO2016107879A3 (en) 2016-08-25

Family

ID=55135190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/081369 WO2016107879A2 (en) 2014-12-30 2015-12-29 New use of angiotensin ii receptor agonists

Country Status (1)

Country Link
WO (1) WO2016107879A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
GB201917327D0 (en) 2019-11-28 2020-01-15 Vicore Pharma Ab New pharmaceutical use
KR20230004501A (en) 2020-03-19 2023-01-06 바이코어 파마 아베 New Compounds Useful for the Treatment and/or Prevention of Diseases, Disorders, or Conditions Associated with Angiotensin II
GB202004094D0 (en) 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202013721D0 (en) 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
WO2022200785A1 (en) 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
GB202104033D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202104038D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
WO2023281271A1 (en) 2021-07-09 2023-01-12 Vicore Pharma Ab New selective angiotensin ii compounds
WO2024149712A1 (en) 2023-01-09 2024-07-18 Vicore Pharma Ab Selective angiotensin ii compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026644A1 (en) * 1997-11-26 1999-06-03 University Of Southern California Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
WO1999040107A2 (en) * 1998-02-09 1999-08-12 University Of Southern California Method of promoting keratinocyte proliferation
US6248587B1 (en) * 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
WO2004085420A1 (en) * 2003-03-24 2004-10-07 Vicore Pharma Ab Bicyclic compounds useful as angiotensin ii agonists
WO2006109058A1 (en) * 2005-04-12 2006-10-19 Vicore Pharma Ab New bicyclic angiotensin ii agonists
US20120035232A1 (en) * 2010-06-11 2012-02-09 Vicore Pharma Ab Use of angiotensin ii agonists
WO2012070936A1 (en) * 2010-11-23 2012-05-31 Lanthiopep B.V. Novel angiotensin type 2 (at2) receptor agonists and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026644A1 (en) * 1997-11-26 1999-06-03 University Of Southern California Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6248587B1 (en) * 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
WO1999040107A2 (en) * 1998-02-09 1999-08-12 University Of Southern California Method of promoting keratinocyte proliferation
WO2004085420A1 (en) * 2003-03-24 2004-10-07 Vicore Pharma Ab Bicyclic compounds useful as angiotensin ii agonists
WO2006109058A1 (en) * 2005-04-12 2006-10-19 Vicore Pharma Ab New bicyclic angiotensin ii agonists
US20120035232A1 (en) * 2010-06-11 2012-02-09 Vicore Pharma Ab Use of angiotensin ii agonists
WO2012070936A1 (en) * 2010-11-23 2012-05-31 Lanthiopep B.V. Novel angiotensin type 2 (at2) receptor agonists and uses thereof

Also Published As

Publication number Publication date
WO2016107879A2 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
WO2016107879A3 (en) New use of angiotensin ii receptor agonists
EP3807927A4 (en) Tsv as pad
MX2017010993A (en) Angiotensin ii receptor agonist for treating pulmonary fibrosis.
WO2015143188A8 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
EP3116969A4 (en) Composition for tungsten cmp
EP3116970A4 (en) Composition for tungsten cmp
EP3154594A4 (en) Fap-activated therapeutic agents, and uses related thereto
EP3117451A4 (en) Composition for tungsten cmp
EP3193397A4 (en) Binder composition for storage device electrode, slurry for storage device electrode, storage device electrode, and storage device
EP3423094A4 (en) Gfral receptor therapies
EP3122344A4 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EP3122346A4 (en) Trka kinase inhibitors, compositions and methods thereof
EP3210663A4 (en) Organic silicon composition, and preparation and use thereof
EP3443966A4 (en) Composition for treating chronic pulmonary disease, comprising exosome derived from thrombin-treated stem cell
EP3137074A4 (en) Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
PL3380508T3 (en) Thermostable fgf2 polypeptide, use thereof
EP3130258A4 (en) Seat pad
EP3121847A4 (en) Aluminium-silicon carbide composite, and power-module base plate
WO2015200534A3 (en) Small molecule agonists of neurotensin receptor 1
EP3391784A4 (en) Seat pad
EP3200841A4 (en) Cardiosphere-derived cells (cdcs) as therapeutic agents for pulmonary hypertension
EP3545796A4 (en) Seat pad
ZA201606276B (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
PH12018501844A1 (en) Liraglutide in cardiovascular conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15823607

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15823607

Country of ref document: EP

Kind code of ref document: A2